Skip to main content
. 2024 Jan 19;10:183–190. doi: 10.1016/j.ijregi.2024.01.006

Table 2.

Comparison of demographic and medical variables with the pulmonary involvement of all abnormalities based on lung computed tomography.

Pulmonary involvement of all abnormalities
<10%
10-25%
25-50%
>50%
n,% P-value
OR
(95% CI)
n,% P-value
OR
(95% CI)
n,% P-value
OR
(95% CI)
n,% P-value
OR
(95% CI)
Age groups
(n, %)
<60
(n = 79)
35 (44.3) >0.05
1.12
(0.78-1.62)
32 (40.5) >0.05
0.80
(0.57-1.13)
04
(5.1)
>0.05
1.03
(0.95-1.11)
08 (10.1) >0.05
0.92
(0.85-1.00)
≥60
(n = 81)
32 (39.5) 41 (50.6) 06
(7.4)
02 (2.5)
Variants
(n, %)
Alpha
(n = 26)
13 (50.0) >0.05 06 (23.1) <0.05 04 (15.4) <0.05 03 (11.5) <0.05
Delta
(n = 98)
36 (36.7) 50 (51.0) 06 (6.1) 06 (6.1)
Omicron
(n = 36)
18 (50.0) 17 (47.2) 0 (0.0) 01 (2.8)
Vaccine None
(n = 105)
50 (47.6) >0.05 41
(39.0)
<0.05 09
(8.6)
>0.05 05
(4.0)
>0.05
1 dose
(n = 17)
05 (29.4) 08 (47.1) 01 (5.9) 03 (17.5)
≥2 doses
(n = 38)
12 (31.6) 24 (63.2) 00 (0.0) 02 (5.3)
Oxygen therapies Not used
(n = 68)
42 (61.8) <0.05 21
(30.9)
<0.05 03
(4.4)
>0.05 02 (2.9) <0.05
Mask cannula
(n = 68)
19 (27.9) 37
(54.4)
04
(5.9)
08 (11.8)
Ventilator
(n = 24)
06 (25.0) 15
(62.5)
03
(12.5)
0
(0.0)
Severities Non severe
(n = 72)
45
(62.5)
<0.001
2.00
(1.45-2.76)
22
(30.6)
<0.001
3.13
(1.63-6.04)
03 (4.2) >0.05
0.96
(0.89-1.04)
02
(2.8)
>0.05
0.94
(0.87-1.01)
Severe
(n = 88)
22
(25.0)
51
(58.0)
07 (8.0) 08
(9.1)
Treatment outcomes Survive
(n = 140)
63 (45.0) <0.05
2.25
(0.92-5.51)
60
(42.9)
>0.05
1.63
(0.88-3.02)
08
(5.7)
>0.05
1.63 (0.88-3.02)
09
(6.4)
>0.05
0.99
(0.88-1.10)
Death
(n = 20)
04 (20.0) 13
(65.0)
02
(10.0)
01 (5.0)

CI, confidence interval; OR, odds ratio.